---
layout: default
---
<div class="home">
  <div class="materials-wrap">
    <h2 class="module-header">MIT 6.881/20.S948    Machine Learning Based Therapeutic Design    3-0-3 (G)</h2>


    <h2 class="module-header">Course description</h2>
    <p>Advanced seminar on computational methods in the design and analysis of human therapeutics, including vaccines,  small molecules, biologics, cell based therapies, and synthetic biology approaches. Lectures will present recent results on computational methods on vaccine design, molecular design and optimization drawing upon advances in machine learning.  Recitations will include presentations by students on recent research results related to the computational design of therapeutics and efficacy. Topics include protein design, antibody optimization, vaccine design, small molecule design and characterization, and the engineering of viruses and cell lines for therapeutic effect. Experts from industry and faculty will present their views of the promise of computational approaches, what is working, and what is needed.
    </p>

    <h2 class="module-header">Syllabus and schedule</h2>
    <table class="table">
        <th>Date</th><th>Title</th><th>Speaker</th><th>Role</th><th>Affiliation</th><th>Papers</th>
        <tr><td>02/03</td><td>T-cell vaccines</td><td>David Gifford</td><td>Professor</td><td>MIT</td><td></td></tr>
        <tr><td>02/10</td><td>Synthetic, biodegradable lipid nanoparticles for gene therapy and gene editing</td><td>Qiaobing Xu</td><td>Professor</td><td>Tufts University</td><td>
            <a href="https://www.pnas.org/content/118/10/e2020401118">Qiu2021</a>
            <a href="https://www.science.org/doi/10.1126/sciadv.abf1244">Chen2021</a>
            <a href="https://www.science.org/doi/10.1126/sciadv.abb4429">Ma2020</a>
            </td></tr>
        <tr><td>02/17</td><td>COVID-19: Developing a Vaccine During a Pandemic</td><td>Dan Barouch</td><td>Professor</td><td>Harvard Medical School, Center for Virology and Vaccine Research</td><td></td></tr>
        <tr><td>02/24</td><td>Regenerative medicine for Type 1 Diabetes</td><td>Adrian Veres</td><td>Postdoctoral Fellow</td><td>Harvard University</td><td></td></tr>
        <tr><td>03/03</td><td>Data-driven small molecule design and synthesis</td><td>Connor Coley</td><td>Professor</td><td>MIT</td><td>
            <a href="https://pubs.acs.org/doi/10.1021/acs.accounts.8b00087">Coley2018</a>
            <a href="https://pubs.rsc.org/en/content/articlelanding/2021/sc/d0sc06805e">Graff2021</a>
            <a href="https://arxiv.org/abs/2110.06389">Gao2021</a>            
            </td></tr>
        <tr><td>03/10</td><td>Using computational methods to address druggability and drug discovery challenges</td><td>Jose Duca</td><td>Global Head of Computer-Aided Drug Discovery</td><td>Novartis</td><td></td></tr>
        <tr><td>03/17</td><td>ML-driven small molecule selection in drug discovery</td><td>Jeremy Jenkins</td><td>US Head, Chemical Biology & Therapeutics</td><td>Novartis</td><td>
            <a href="https://www.nature.com/articles/nrd.2017.232">Schneider2017</a>
            <a href="https://chemrxiv.org/engage/chemrxiv/article-details/60f5d0b888044385cfe22cdc">Godinez2021</a>
            </td></tr>
        <tr><td>03/24</td><td>Spring Break</td><td>Enjoy your break!</td><td></td><td></td><td></td></tr>
        <tr><td>03/31</td><td>Synthetic Biology Approaches to Disease Therapeutics</td><td>Ron Weiss</td><td>Professor</td><td>MIT</td><td></td></tr>
        <tr><td>04/07</td><td>Antibody CDR Design  Using High-Capacity Machine Learning</td><td>Stefan Ewert</td><td>Associate Director</td><td>Novartis</td><td></td></tr>
        <tr><td>04/14</td><td>T-cell therapeutics</td><td>Michael Birnbaum</td><td>Professor</td><td>MIT</td><td></td></tr>
        <tr><td>04/21</td><td>ML based reprogramming of gene expression</td><td>Brendan Frey</td><td>Founder & CEO</td><td>Deep Genomics</td><td></td></tr>
        <tr><td>04/28</td><td>TBD</td><td>TBD</td><td>TBD</td><td>TBD</td><td></td></tr>
        <tr><td>05/05</td><td>CRISPR and protein design</td><td>Han Altae-Tran</td><td>PhD student</td><td>Broad Institute of MIT and Harvard</td><td></td></tr>
    </table>

    <h2 class="module-header">Class meeting times and places</h2>
    <ul>
        <li>Lecture: Thursday 11AM-12:30PM MIT Room 32-155</li>
        <li>Recitation: Tuesday 11AM-12:30PM MIT Room 32-155 (first recitation February 8, 2022)</li>
    </ul>

    <h2 class="module-header">Office hours</h2>
    <div class="materials-item">
        David Gifford (gifford@mit.edu): Office hours by appointment
    </div>
    <div class="materials-item">
       Hyunjin Park (hyunjinp@mit.edu): TBD, Stata Center, G5 Lounge
    </div>

    <h2 class="module-header">Grading</h2>
    <p><p>There will be two problem sets.  Problem Set 1 explores the design of contemporary mRNA COVID-19 vaccines. Problem Set 2 explores the use of deep learning for antibody design.   Students will also present papers during recitation. If you will need special accomodations, please email Student Support Services: s3-support@mit.edu. We will be happy to accomodate!</p>
  </div>
</div>
